Navigation Links
Micromet Closes $80.5 Million Public Offering of Common Stock
Date:8/4/2009

BETHESDA, Md., Aug. 4, /PRNewswire-FirstCall/ --Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the closing of its previously announced public offering of 14,000,000 shares of common stock. Micromet also announced that the underwriters for the offering have exercised in full their over-allotment option to purchase an additional 2,100,000 shares, bringing the total shares sold to 16,100,000 at a price of $5.00 per share for gross proceeds of $80.5 million. The Company received net proceeds of approximately $75.0 million, after deducting underwriting discounts and estimated offering expenses.

Piper Jaffray & Co. acted as the sole book running manager with RBC Capital Markets and Merriman Curhan Ford as co-managers in this offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional mon
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
2. Micromet Announces Pricing of Public Offering of Common Stock
3. Micromet Announces Public Offering of Common Stock
4. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
5. Micromet Added to Russell 3000 Index
6. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
7. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
8. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
9. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
10. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
11. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)...  The Diabetes Research Institute (DRI), a Center ... School of Medicine, announced today that the first ... the first time a novel transplant technique for ... Phase I/II study builds upon decades of progress ... first step toward the development of the DRI ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Impressive Acheivements  DiaCardio wins 1 st place  ... The competition, led in Israel by venture ... startups from countries including the US, China , ... Latin America .  Impressive achievement for ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
(Date:8/25/2015)... 25, 2015   WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical ... with 20 years of operations in China ... signed an agreement whereby WuXi,s Laboratory Testing Division (LTD) ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... 2009 (EurekAlert)--Advanced Cell Technology, Inc. (OTC:ACTC.PK) and its ... and efficacy of human embryonic stem cell (hESC)-derived ... suitable for human clinical trials. Two important early ... for the treatment of age-related macular degeneration and ...
... Barriers to Care and the Threatening Impact of Diabetes in ... panel of clinical and policy experts gathered by Novo Nordisk ... the exponential growth of diabetes in America. The universal ... the American Diabetes Association (ADA), was that the cost of ...
... AMSTERDAM, June 12 , ... Elsevier today announced a new partnership agreement ... science researchers to,search, discover, and share knowledge locked within ... allows for an,integration of NextBio,s unique set of ontology-based ...
Cached Biology Technology:Assessment of safety and efficacy of human embryonic stem cell therapy 2Assessment of safety and efficacy of human embryonic stem cell therapy 3Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit 2Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit 3Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit 4Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit 5Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 2Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 3Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 4
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... "swine flu" in 1976 might provide individuals with some ... to new research from St. Jude investigators. Researchers ... mounted an enhanced immune response against both the 2009 ... that circulated during the 2008-09 flu season. The work ...
... Scientists at The University of Nottingham have discovered the gene ... parts after amputation including a whole head and brain. ... piece in the scientific jigsaw that could one day make ... a real possibility. The research led by Dr ...
... CA April 22, 2010 Scientists at The Scripps ... Foundation (GNF) have shed new light on the molecular mechanism ... from a sizzling stove. In addition to contributing to our ... to new therapies for conditions such as acute or chronic ...
Cached Biology News:Study links 1976 'swine flu' shot to stronger immune response to 21st century pandemic flu 2Study links 1976 'swine flu' shot to stronger immune response to 21st century pandemic flu 3Body builders -- the worms that point the way to understanding tissue regeneration 2New Scripps Research and GNF study helps explain how we can sense temperatures 2New Scripps Research and GNF study helps explain how we can sense temperatures 3New Scripps Research and GNF study helps explain how we can sense temperatures 4
... vaccinia virus is a type I eukaryotic ... superhelical turns (also called right- and left-handed ... of the reaction is a covalently closed, ... superhelical turns. DNA Topoisomerase I does not ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: